How it Works

Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It mimics the biological actions of G-CSF to increase the production of white blood cells, specifically neutrophils, that play a key role in the body's immune system. 

How it’s Administered

• Subcutaneous injection (under the skin)
• Intravenous infusion (through a vein)

Who Should Take G-CSF 

• Indicated to decrease infection incidence in patients with non-myeloid malignancies receiving anticancer drugs that suppress the immune system. 
• Indicated for long-term administration to reduce the incidence and duration of sequelae of neutropenia in symptomatic patients with severe chronic neutropenia 
• Indicated to reduce the duration of low neutrophil blood counts (a type of white blood cell) and its related symptoms in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.
• Indicated for mobilizing autologous peripheral blood progenitor cells (PBPCs) into the peripheral blood for collection by leukapheresis, a procedure in which white blood cells are collected from a patient.

Who Shouldn’t Take G-CSF  

• Patients with a severe allergy to filgrastim or its components, like  E.coli-derived proteins.

The Most Common Side Effects of Taking G-CSF Include:

• Nausea, vomiting, diarrhea
• Bone pain, fever, fatigue, rash, 
• Numbness, headache, nosebleeds 
• Low platelet count
• Alopecia (hair loss)

Commonly Used in Acute Myeloid Leukemia With

• Stem cell collection or white blood cells collection.

TAKE A LOOK AT THE AVAILABLE CLINICAL TRIALS FOR AML

FOR MORE INFORMATION CLICK HERE

Date last updated 12/22/22